Current perceptions of the term Clinical Pharmacy and its relationship to Pharmaceutical Care:a survey of members of the European Society of Clinical Pharmacy by Dreischulte, Tobias & Fernandez-Llimos, Fernando
                                                              
University of Dundee
Current perceptions of the term Clinical Pharmacy and its relationship to
Pharmaceutical Care
Dreischulte, Tobias; Fernandez-Llimos, Fernando
Published in:
International Journal of Clinical Pharmacy
DOI:
10.1007/s11096-016-0385-3
Publication date:
2016
Document Version
Peer reviewed version
Link to publication in Discovery Research Portal
Citation for published version (APA):
Dreischulte, T., & Fernandez-Llimos, F. (2016). Current perceptions of the term Clinical Pharmacy and its
relationship to Pharmaceutical Care: a survey of members of the European Society of Clinical Pharmacy.
International Journal of Clinical Pharmacy, 38(6), 1445-1456. DOI: 10.1007/s11096-016-0385-3
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Introduction 1 
The "Clinical Pharmacy" movement is commonly believed to have its origin among a group of 2 
students at the University of Michigan in the early 1960s, where Don Francke, the alleged “Father of 3 
Clinical Pharmacy”, was teaching1, 2, although the term "Clinical Pharmacy" appeared in the 4 
literature as early as 1952.3 When David Burkholder, one of Don Francke’s students, finished his 5 
degree and moved to the University of Kentucky, he promoted the involvement of pharmacists in 6 
clinical decision-making via drug information.1, 2 The term Clinical Pharmacy was almost immediately 7 
adopted in Europe.4   8 
Since that time, a series of definitions of Clinical Pharmacy have emerged, and table 1 contains an 9 
illustrative collection of definitions originating from the United States and Europe. Although all listed 10 
definitions agree that Clinical Pharmacy is concerned with the use of medicines or its effects, there 11 
are differences. For example, some authors describe Clinical Pharmacy as a body of knowledge5, 12 
rather than a professional practice that draws on or applies such knowledge, and some definitions 13 
describe the aims of Clinical Pharmacy in terms of improving processes (“rational and appropriate 14 
use of medicinal products and devices” 6), while others place emphasis on achieving optimal 15 
outcomes for individual patients.5,7 The term Pharmaceutical Care has been used since 19758 , also 16 
with different definitions, the most widely cited to date being Hepler and Stand’s “responsible 17 
provision of drug therapy for the purpose of achieving definite outcomes that improve a patient’s 18 
quality of life.”9  19 
----------------------------------Please, insert table 1 approximately here -------------------------------------- 20 
Both terms have been used to help establish a new field of professional activity that focuses on the 21 
therapeutic use of medicines and drug therapy outcomes, as opposed to their development or 22 
manufacturing, but it is unclear whether and how the terms differ and whether the distinction 23 
should be maintained. For example, Barber suggested in 2001 that the term Pharmaceutical Care 24 
placed an emphasis on patient’s subjective rather than objective (scientifically determined) drug 25 
therapy needs, but argued that “the future of pharmacy depends on a philosophy that bring(s) 26 
together” both.10  Other authors suggest that the distinction may be related to the setting, arguing 27 
that the term ‘clinic’ invites associations with the hospital sector. 11,12 Possibly in response, some 28 
countries use the term Pharmaceutical Care primarily or exclusively in the community pharmacy 29 
setting. It has been suggested in the early 1990s to abandon the term Clinical Pharmacy, because it is 30 
outdated11, while others call for an unambiguous definition and accurate use of the term in 31 
practice.12  32 
Compiling the key components and core aims of Clinical Pharmacy and Pharmaceutical Care could 33 
facilitate the creation of a global definition of Clinical Pharmacy and clarify its relationship to 34 
Pharmaceutical Care.13 However, in order to gain support for a common definition, current 35 
differences in the definition and use of the term  across different countries and health care settings 36 
should be considered.14  37 
Aims of the study 38 
The primary aim was therefore to identify current disagreements among pharmacists from different 39 
countries and professional backgrounds regarding what the term Clinical Pharmacy encompasses 40 
and whether and how it differs from Pharmaceutical Care. To further inform discussions around a 41 
harmonised definition of Clinical Pharmacy, a secondary aim was to explore the extent to which 42 
pharmacists with an interest in Clinical Pharmacy were willing to accept responsibility for drug 43 
therapy outcomes. 44 
Methods 45 
Survey development and validation 46 
We drafted a survey targeting potential areas of disagreement around the term Clinical Pharmacy 47 
identified by members of an ESCP steering committee on ‘The future of Clinical Pharmacy’ based on 48 
their experience. These potential disagreements included whether Clinical Pharmacy was solely a 49 
term to describe a set of professional activities, what the specific activities were, who could provide 50 
them in which setting, and to which end, and whether and how it differed from Pharmaceutical 51 
Care. 52 
The draft survey was subjected to a 2-round content validation exercise, in which 9 ‘experts’ 53 
(selected by virtue of having substantive experience in pharmacy practice and/or academia) from 9 54 
countries (pragmatically selected for geographical spread from countries with representation in 55 
ESCP: Sweden, the United Kingdom, the Netherlands, Belgium, Germany, Switzerland, France, Italy 56 
and Czech republic)rated each item with respect to its clarity of wording and relevance to informing 57 
a harmonised definition of Clinical Pharmacy or Pharmaceutical Care on a 4 point scale (1 = Not 58 
relevant, 2 = Unable to assess relevance without item revision, 3 = Relevant but needs minor 59 
alteration, 4 = Very relevant and succinct) and were invited to suggest additional items. Items 60 
included in the draft survey were revised in light of experts’ comments and those items that 61 
achieved a median rating of 3 or higher in the second round were included in the survey.  62 
The final survey comprised 7 questions and is provided in the online appendix. Questions 1 to 5 63 
listed a number of (1) professional activities, (2) providers, (3) settings, (4) aims and (5) general 64 
descriptors  and asked participants to state their personal opinion as to whether each item 65 
constituted (a) ‘Clinical Pharmacy only’, (b) ‘Pharmaceutical Care  only’, (c) both or (d) neither.  66 
In order to examine to which extent Hepler and Strand’s stipulation that pharmacist’s patient 67 
oriented services should be provided ‘responsibly’ resonated with participant’s attitudes towards 68 
their own practice, questions 6 and 7 asked them to state their willingness as pharmacists to accept 69 
(a) ethical responsibility, (b) legal responsibility or (c) neither for services necessary to achieve 70 
desired outcomes (drug therapy effectiveness, safety, patient centeredness and cost-effectiveness). 71 
We distinguished between (6) ’current’ and (7) ‘ideal’ working conditions, respectively, in order to 72 
account for the possibility that pharmacists’ willingness to accept responsibility may be limited by 73 
currently available resources (e.g. time, access to medical notes) or support from their environment 74 
(e.g. employers or other health care professionals). For the purposes of this survey, ‘ethical 75 
responsibility’ was defined as a moral obligation to provide necessary services to achieve these 76 
outcomes, whereas ‘legal responsibility’ was defined as legal accountability for a failure to provide 77 
necessary services.  78 
Recruitment of survey participants 79 
An invitation to participate (with 2 reminders) in the online version of the survey was sent out by 80 
email in September 2014 to 1,285 individuals from 57 countries, who were either current ESCP 81 
members or had registered for one or more ESCP symposia since 2012.  82 
Outcome measures and data analysis 83 
In order to identify key areas of disagreement around the term Clinical Pharmacy (objective 1), we 84 
examined agreement between participants for each item listed in questions 1 to 5 regarding 85 
whether it applied to Clinical Pharmacy or not.  To this end, participants’ scores were dichotomised 86 
into (a) ‘Clinical Pharmacy only’ or ‘both’ vs (b) ‘Pharmaceutical Care only’ or ‘Neither’. In order to 87 
identify key areas of disagreement around the relationship between Clinical Pharmacy and 88 
Pharmaceutical Care (objective 2), we examined to which extent participants who linked each item 89 
to Clinical Pharmacy distinguished between the two terms, i.e. rated that the item applied to Clinical 90 
Pharmacy only but not Pharmaceutical Care . For both  objectives (1) and (2), ‘strong agreement’ 91 
was defined as 90% or more of respondents opting for either option, ‘agreement’ as more than 80%  92 
but less than 90% opting for either option, and ‘disagreement’ otherwise.  93 
For items with disagreement regarding whether they applied to Clinical Pharmacy (objective 1), we 94 
used logistic regression to investigate whether the following participant characteristics were 95 
independently associated with linking the item to Clinical Pharmacy (i.e. responded “Clinical 96 
Pharmacy only” or “both” vs “Pharmaceutical Care only” or “Neither”): geographical origin (classified 97 
as Europe North, Europe West, Europe East, Europe South, non-European), year of qualification as a 98 
pharmacist (classified as before versus after the year 2000), academic activity (classified as either 99 
teaching or conducting research versus no such activity), working in a hospital. We examined 100 
univariate associations first. Variables that were significant at the p=0.05 level in univariate analysis 101 
were included in a multivariate model. Other variables that did not achieve this level of significance 102 
in univariate analysis were retained if their addition to the model altered the point estimates of 103 
other variables by 10% or more. In the multivariate model, associations were defined as significant 104 
at the p=0.05 level.” 105 
 106 
In order to examine participants’ perception of the relationship between Clinical Pharmacy and 107 
Pharmaceutical Care further, we pooled ‘CP only’, ‘PC only’ and ‘both’ ratings across questions at 108 
participant level and examined the proportion of participants who fell into each of five groups 109 
representing potential relationships between CP and PC (see figure 1). For questions 6 and 7, we 110 
considered the proportions of participants willing to accept any form of responsibility, i.e. ‘ethical ‘or 111 
‘legal’, and of those willing to accept ‘any’ and ‘legal’ responsibility under ‘ideal’ but not ‘current’ 112 
working conditions, respectively.   113 
----------------------------------Please, insert figure 1 approximately here -------------------------------------- 114 
Ethical issues 115 
All procedures performed were in accordance with the ethical standards of National Health Service 116 
research ethics committees and with the 1964 Helsinki declaration and its later amendments. The 117 
study did not include patients or other vulnerable groups. Ethical approval was not required. 118 
. 119 
Results 120 
Survey participants 121 
Table 2 shows that a total of 263 participants from 54 different countries completed the 122 
questionnaire (response rate 20.5%). The majority of participants (90.1%) were from Europe and the 123 
vast majority of respondents were qualified pharmacists (97.3%). Just over half of respondents 124 
(57.4%) had completed their pharmacy training before the year 2000. Just under half of respondents 125 
primarily worked in hospital settings (48.7%) and 11.4% primarily worked in community pharmacy 126 
settings (11.4%). The majority of respondents had been members of ESCP for one year or longer 127 
(60.1%), with 15.2% serving or having previously served on an ESCP committee.  128 
 129 
----------------------------------Please, insert table 2 approximately here -------------------------------------- 130 
 131 
Opinions regarding the term Clinical Pharmacy  132 
Figure 2 shows the proportions of participants who linked each item to ‘Clinical Pharmacy only’, 133 
‘Pharmaceutical Care only’ or ‘both’, with the remainder linking the item to ‘neither’. 134 
General understanding of the terms - There was strong agreement among participants that Clinical 135 
Pharmacy referred to a ‘scientific discipline’ (94.2%) and ‘set of professional activities’ (93.9%), and 136 
agreement for ‘professional behaviour’ (89.7%), and ‘set of professional values or principles’ 137 
(89.4%).  138 
Outcomes targeted - There was strong agreement among participants that Clinical Pharmacy 139 
targeted medication safety (95.4%) and effectiveness (95.1%) and agreement that Clinical Pharmacy 140 
targeted patient-centeredness (86.0%) and cost-effectiveness (83.5%).  141 
 142 
----------------------------------Please, insert figure 2 approximately here -------------------------------------- 143 
 144 
Professional activities - There was strong agreement that the term Clinical Pharmacy accommodated  145 
‘drug therapy optimisation at patient level (93.2%)’, ‘laboratory monitoring of drug therapy (93.5%)’ 146 
and ‘treatment individualisation (93.9%)’, and there was agreement that it encompassed ‘managing 147 
an individual’s drug therapy(86.7%)’, ‘drug therapy optimisation at provider level (87.5%)’, ‘ensuring 148 
accurate drug history and transfer of information(88.2%)’, ‘informative counselling (87.1%)’ and 149 
‘compassionate counselling (81.0%)’.  However, participants disagreed regarding the remaining 150 
activities, with the following proportions of participants not linking the following activities to Clinical 151 
Pharmacy: ‘compounding (71.1%)’, ‘drug logistics (60.5%)’, ‘filling a prescription/ dispensing 152 
(54.8%)’, ‘drug administration (42.6%)’ and ‘public health promotion (43.5%)’.  153 
Table 3 shows that compared to participants from Western European countries, those from 154 
Southern European countries were significantly more likely to link ‘compounding’ (adjusted OR 2.93 155 
[95% CI 1.37, 6.29], p=0.008) to Clinical Pharmacy and those from Southern (adjusted OR 3.21 [95% 156 
CI 1.53, 6.74], p=0.001) and Eastern (adjusted OR 2.36 [95% CI 1.08, 5.13], p=0.022) European 157 
countries were significantly more likely to link ‘drug logistics’ to Clinical Pharmacy. Having an 158 
academic background was significantly associated with not linking ‘dispensing’ (adjusted OR 0.43 159 
[95% CI 0.24, 0.76], p=0.004), ‘compounding’ (adjusted OR 0.33 [95% CI 0.20, 0.69], p=0.002), and 160 
‘drug logistics’ (adjusted OR 0.40 [95% CI 0.22, 0.75], p=0.004) to Clinical Pharmacy, as was working 161 
in a hospital with respect to ‘drug logistics’ (adjusted OR 0.33 [95% CI 0.18, 0.59], p<0.001).  162 
----------------------------------Please, insert table 3 approximately here -------------------------------------- 163 
Providers - There was strong agreement that pharmacists could provide Clinical Pharmacy services 164 
(97%), and that informal carers (e.g. relatives) could not provide such services (93.1%), but  165 
disagreement whether ‘other health care professionals’ could (74.8% of participants disagreed with 166 
this). Compared to participants from Western European countries, those from Southern European 167 
countries (adjusted OR 0.36 [95% CI 0.13, 0.98], p=0.045) were significantly less likely to state that 168 
non-pharmacist health care professionals could provide Clinical Pharmacy services. 169 
Setting - There was strong agreement among participants that Clinical Pharmacy services could be 170 
provided in a ‘Hospital Ward or outpatient clinic (96.5%)’ and in a ‘Hospital pharmacy (92.7%)’, but 171 
disagreement regarding non-hospital settings (a ‘physician’s practice’ was not considered a site for 172 
provision of clinical pharmacy services by 24.1%, ‘community pharmacy’ by 29.3%, a ‘patient’s 173 
home’ by 31.7%, and ‘any other private or public space’ by 45.6% of participants, respectively).  174 
Compared to participants from Western European countries, those from Northern European 175 
countries (adjusted OR 0.36 [95% CI 0.13, 0.98], p=0.045) were significantly more likely to state that 176 
Clinical Pharmacy services could be provided in a physician’s practice (adjusted OR 0.36 [95% CI 0.13, 177 
0.98], p=0.045) while participants from Southern European countries were less likely to state that 178 
Clinical pharmacy services could be provided in community pharmacies. None of the participant 179 
characteristics tested was significantly associated with excluding non-hospital settings as sites for 180 
the provision of Clinical Pharmacy services. 181 
 182 
Relationship between Clinical Pharmacy and Pharmaceutical Care  183 
There was disagreement regarding the relationship between the two terms, with less than 80% of 184 
participants providing ratings consistent with either of the options A to E illustrated in figure 1. 185 
Nevertheless, a majority of participants (76.0%) held that Clinical Pharmacy and Pharmaceutical Care 186 
partially overlapped with both also having distinct elements (figure 1, option B). Fewer participants 187 
believed that Pharmaceutical Care was part of Clinical Pharmacy (Option E: 11.0%), that Clinical 188 
Pharmacy was part of Pharmaceutical Care (Option D: 6.8%), that Clinical Pharmacy and 189 
Pharmaceutical Care were synonymous (Option C: 5.7%), and that Clinical Pharmacy and 190 
Pharmaceutical Care were completely distinct (Option A: 0.3%) with respect to items included in this 191 
survey. 192 
 193 
General understanding of the terms - Among participants linking each descriptor to Clinical 194 
Pharmacy, there was strong agreement that both Clinical Pharmacy and Pharmaceutical Care could 195 
be generally described as sets of ‘professional activities’ (94.9%), ‘behaviours’ (97.0%), and 196 
‘professional values or principles’ (95.9%), but there was disagreement as to whether 197 
Pharmaceutical Care also constituted a ‘scientific discipline (31.7% disagreed with this). Having 198 
qualified as a pharmacist in 2000 or later was significantly associated with stating that ‘Clinical 199 
Pharmacy’ but not ‘Pharmaceutical Care’ constituted a ‘scientific discipline’.  200 
 201 
Outcomes targeted – There was agreement that both Clinical Pharmacy and Pharmaceutical Care 202 
targeted medication safety, effectiveness and patient centeredness but disagreement whether 203 
Pharmaceutical Care also targeted cost-effectiveness (23.4% disagreed with this). None of the 204 
participant characteristics tested was significantly associated with linking cost-effectiveness to 205 
‘Clinical Pharmacy’ but not ‘Pharmaceutical Care’. 206 
 207 
Professional activities - There was disagreement as to whether ‘Pharmaceutical Care’  also 208 
comprised the following specific activities (% negating this): ‘managing an individual’s drug therapy , 209 
e.g. supporting the patient to take his/her medicines as agreed’ (20.2%), ‘drug therapy optimisation 210 
at patient level, e.g. recommending a certain antibiotic for an individual patient’ (33.1%), ensuring 211 
accurate drug history and transfer of information (33.6%), ‘drug therapy optimisation at provider 212 
level, e.g. developing and disseminating a new guideline on antibiotic prescribing’ (50.0%), 213 
‘treatment individualisation, e.g. via therapeutic drug monitoring and pharmacogenetic testing 214 
(50.6%)’, and ‘laboratory monitoring of drug therapy, e.g. renal function’(56.1%). None of the 215 
participant characteristics tested was significantly associated with linking respective activities to 216 
‘Clinical Pharmacy’ but not ‘Pharmaceutical Care’. 217 
 218 
Providers and settings - There was agreement or strong agreement that Clinical Pharmacy and 219 
Pharmaceutical Care did not differ with respect to providers or settings  220 
 221 
Pharmacists’ willingness to accept responsibility 222 
Figure 3 shows that under the conditions of their current working practice, over 80% of respondents 223 
were willing to accept some form of responsibility, with little difference between the four different 224 
domains (94.3% safety, 89.7% effectiveness, 87.1% patient-centeredness, 85.1% cost-effectiveness). 225 
However, the proportions of participants who were willing to assume legal responsibility were much 226 
lower: safety (32.7%), effectiveness (17.9%), patient-centeredness (17.1%) and cost-effectiveness 227 
(20.3%).  228 
Under ideal working conditions, the proportions of participants being willing to assume some form 229 
of responsibility increased slightly, but the proportions willing to assume legal responsibility at least 230 
doubled (safety: 64.3% , effectiveness: 49.2% , patient-centeredness: 46.2%, cost-effectiveness: 231 
44.0%).  232 
----------------------------------Please, insert figure 3 approximately here -------------------------------------- 233 
 234 
 235 
Discussion 236 
Key findings 237 
We found that a panel of 263 pharmacists who had previously attended European Society of Clinical 238 
Pharmacy symposia, agreed that the term Clinical Pharmacy encompassed a scientific discipline as 239 
well as a set of professional activities, behaviours and values or principles and that the aims of 240 
Clinical Pharmacy were to improve medication safety, effectiveness, cost-effectiveness as well as 241 
patient-centeredness. Survey participants also agreed that Clinical Pharmacy practice comprised a 242 
range of activities at both population and individual patient levels and that Clinical Pharmacy 243 
services could be provided by pharmacists but not by informal carers in hospital settings. In contrast, 244 
there was disagreement as to whether traditional pharmacy activities (compounding, drug logistics, 245 
dispensing), drug administration or public health promotion constituted Clinical Pharmacy activities, 246 
where  differences in opinion regarding one or more of these items were associated with the 247 
presence or absence of an academic background, working in a hospital and geographical residence. 248 
There was also disagreement whether non-pharmacist health care professionals could provide 249 
Clinical Pharmacy services and whether such services could be provided in non-hospital settings. 250 
Approximately three quarters of participants provided ratings that were consistent with Clinical 251 
Pharmacy and Pharmaceutical Care partially overlapping, but there was disagreement as to what the 252 
distinct elements of Clinical Pharmacy were. Over 80% of survey participants were willing to accept 253 
ethical responsibility for processes necessary to achieve desired outcomes. Although less than a 254 
third of participants were willing to accept legal responsibility under their current working 255 
conditions, under ideal working conditions almost two thirds of participants were willing to accept 256 
legal responsibility for medication safety and almost half for effectiveness, patient-centeredness and 257 
cost-effectiveness. 258 
Strengths & Limitations 259 
To our knowledge this is the first survey to identify disagreements regarding the term Clinical 260 
Pharmacy and its relationship to Pharmaceutical Care. The face and content validity of the survey 261 
was established by an expert panel of experienced ESCP members, who were also invited to suggest 262 
additional items, and we therefore believe that the main uncertainties around what constitutes 263 
Clinical Pharmacy were covered. Data was collected from pharmacists from a wide range of 264 
countries and with diverse professional backgrounds and experience, but a limitation to 265 
generalisability is that hospital pharmacists and countries with relatively large numbers of ESCP 266 
members were overrepresented. A further limitation is a relatively low response rate of 20%, 267 
although we do not think that this substantially compromised the identification of key 268 
disagreements around the term Clinical Pharmacy and its relationship to Pharmaceutical Care, the 269 
primary aim of this survey. When asking about pharmacists’ willingness to accept ethical or legal 270 
responsibility, a limitation is that we did not explicitly distinguish between sole vs co-responsibility, 271 
and it is therefore possible that the proportion of pharmacists who were willing to accept some form 272 
of ethical or legal responsibility was underestimated. Similarly, the apparent disagreement regarding 273 
whether Pharmaceutical Care constitutes a “scientific discipline (e.g. a branch of pharmacy)” might 274 
benefit from further exploration as to what constitutes a scientific discipline in the opinion of 275 
stakeholders. We have made no attempt to conduct a conceptual analysis to derive the “true” 276 
meaning of the term Clinical Pharmacy, because the interpretation of the term “clinical” will be 277 
significantly driven by the cultural and political context it is used in. Finally, although defining 278 
disagreement using a cut-off of 80% agreement is arbitrary, we hold that it is a meaningful threshold 279 
to identify priorities for further discussions around a harmonised understanding of the term Clinical 280 
Pharmacy.  281 
Implications 282 
Our survey has established that there is general agreement among participants that Clinical 283 
Pharmacy is a scientific discipline within pharmacy and one area of pharmacy practice that 284 
encompasses a range of professional activities to optimise medicines use, and that the aim is to 285 
improve clinical as well as humanistic and economic outcomes of drug therapy. These findings are 286 
generally consistent with the ESCP describing Clinical Pharmacy as a ‘health specialty, which 287 
describes […] activities and services […]  to […] promote the rational and appropriate use of 288 
medicinal products and devices’ to achieve ‘better health outcomes and a better use of health care 289 
resources’.15 Although ESCP also specifies that Clinical Pharmacy describes activities of ‘pharmacists’ 290 
and clarifies that the word ‘clinical’ should not be taken to restrict such services to hospitals, there 291 
were disagreements among survey participants regarding who could be providers and in which 292 
settings.  293 
 294 
Additionally, and perhaps most importantly, there was disagreement around whether Clinical 295 
Pharmacy also encompassed the more traditional pharmaceutical activities of compounding, 296 
dispensing and drug logistics. Given that the term Clinical Pharmacy has originally been coined to 297 
support a paradigm shift in the pharmacy profession from manufacturing and distributing drug 298 
products to a focus on the therapeutic use of medicines, greater clarity by organisations such as 299 
ESCP about how Clinical Pharmacy differs from traditional pharmacy practice, may support the 300 
intended function of the term. In addition, our finding that participants’ opinions regarding the 301 
specific activities captured by Clinical Pharmacy differed by professional background and 302 
geographical residence highlights that support for a harmonised definition of Clinical Pharmacy 303 
should be sought from both academics and non-academics, and from both those working in hospital 304 
and community settings in all parts of Europe (and beyond). 305 
 306 
The term Pharmaceutical Care has been coined to support the same development within the 307 
pharmacy profession, but the majority of participants distinguished between the terms with distinct 308 
elements for both. However, there was no agreement regarding what the distinct elements were.   309 
One commonly mentioned difference relates to the setting of practice, consistent with our finding 310 
that almost 20% of respondents considered Clinical Pharmacy an exclusively hospital-based activity 311 
while almost 30% held that Pharmaceutical Care was exclusively practiced in community pharmacy. 312 
Future definitions should make it explicit, whether or not the practice of Clinical Pharmacy is setting 313 
specific. A further potential difference relates to the focus of practice. It could be argued that 314 
initially, the focus of Clinical Pharmacy was on process rather than outcome16, and that a key 315 
function of the Pharmaceutical Care concept was to shift the focus from process to patient 316 
outcomes.17 The fact that in their latest definition of Clinical Pharmacy, the American College of 317 
Clinical Pharmacy states that “The practice of Clinical Pharmacy embraces the philosophy of 318 
Pharmaceutical Care […] for the purpose of ensuring optimal patient outcomes”7 can be taken as an 319 
indication that the term Pharmaceutical Care has succeeded in this respect. Nevertheless, even with 320 
this definition, the word “embrace” leaves room for interpretation where (if any) the boundaries 321 
between the two terms lie. In response to ongoing debates around the Pharmaceutical Care concept 322 
18, the Pharmaceutical Care Network Europe has recently defined it  as ‘the pharmacist’s 323 
contribution to the care of individuals in order to optimise medicines use and improve health 324 
outcomes’.19 Clarifying the relationship between Clinical Pharmacy and Pharmaceutical Care as well 325 
as their functions is likely to be mutually beneficial in order to accomplish the paradigm shift within 326 
the pharmacy profession that both terms set out to achieve.  327 
 328 
A further function of the term Pharmaceutical Care (as defined in 19909) was to promote providers 329 
accepting responsibility for drug therapy outcomes. Hepler stated that responsibilities, and not 330 
technical functions, should drive the definition of Clinical Pharmacy20, and theoretical models have 331 
been used to fundament the perception of responsibility acquisition by pharmacists providing 332 
clinical services.21 It is therefore noteworthy that common definitions of Clinical Pharmacy and the 333 
PCNE definition do not include this notion. However, the progression from providing advice on 334 
medicines use to accepting responsibility for patient outcomes may be the next shift in paradigm 335 
that the pharmacy profession has yet to accomplish. Our finding that pharmacists’ willingness to 336 
accept legal responsibility at least doubled under ‘ideal’ compared to ‘current’ working conditions, 337 
suggests that current working environments are perceived as limiting factors. Further research is 338 
required to better understand barriers and facilitators to pharmacists accepting the optimisation of 339 
drug therapy outcomes as their core responsibility as health care professionals. 340 
 341 
Conclusions 342 
The survey demonstrates discrepancies between pharmacists across Europe in their understanding 343 
of the term Clinical Pharmacy and its relationship to Pharmaceutical Care. Based on the survey’s 344 
findings, the main barriers towards a harmonised understanding of the term Clinical Pharmacy relate 345 
to who can provide Clinical Pharmacy services in which settings as well as what the specific activities 346 
are that differentiate Clinical Pharmacy from traditional pharmacy practice and Pharmaceutical Care. 347 
Although ensuring optimal patient outcomes is and continues to be a multidisciplinary task, the 348 
responsibilities of pharmacists within clinical teams should become an area of future debate.   349 
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Figure 1: Illustration of possible relationships between Clinical Pharmacy and Pharmaceutical Care 
 
 
 
A=’Clinical Pharmacy (CP)’ and ‘Pharmaceutical Care (PC)’ are completely distinct (reflected by 
participants rating ‘CP only’ or ‘PC only’ for all items); B=CP and PC partially overlap (reflected by 
participants rating each of ‘CP only’, ‘PC only’ and ‘both’ for one or more items); C=CP and PC completely 
overlap (reflected by participants who stated ‘both’ for all items); D=CP is part of PC ( reflected by 
participants who stated each of ‘PC only’ and ‘both’ for one or more items); E=PC is part of CP (reflected 
by participants who stated each of ‘CP only’ and ‘both’ for one or more items) 
  
Figure 2: Findings of survey questions targeting participants’ understanding of the term Clinical Pharmacy 
and its relationship to Pharmaceutical Care. For each question, the items are ranked in descending order of 
the overall proportions of survey participants linking each item to Clinical Pharmacy. 
 
a. General understanding of the terms Clinical Pharmacy and Pharmaceutical Care 
 
b. Drug therapy outcomes targeted by Clinical Pharmacy and/or Pharmaceutical Care 
 
c. Professional activities that fall under the terms Clinical Pharmacy and/or Pharmaceutical Care 
 
d. Providers of Clinical Pharmacy and/or Pharmaceutical Care services 
 
e. Settings for the provision of Clinical Pharmacy and/or Pharmaceutical Care services 
 
                                                                               Proportion of survey participants [%] 
Figure 3: Findings of survey questions targeting participants’ willingness to accept ethical or legal 
responsibility for providing the services necessary to achieve different drug therapy outcomes, distinguishing 
between a) participants’ most current and b) ideal working conditions, respectively. 
 
a. Willingness to accept responsibility under current working conditions  
 
b. Willingness to accept responsibility under ideal working conditions 
 
                                  Proportion of survey participants [%] 
 
Table 1. Illustrative collection of definitions (original or in their English translation) of the term Clinical Pharmacy highlighting apparent commonalities and differences 
between them 
Author [Year] Country Definition General 
description 
Focus on  
process vs 
outcomes 
Provider Setting 
Hutchinson, 
Burkholder [1971]2 
US The utilization of  a  pharmacist's drug  knowledge as applied to  the  specific 
drug  problems of  an individual patient 
Health care 
practice 
Process  Pharmacist Not 
specified 
Traub et al [1979]22 US The practice of ensuring that the correct patient received the most 
appropriate medication and dose for a specific condition, via a rational 
dosage form and regime, over an appropriate time period; and assisting in 
the prevention, identification and resolution of untoward effects from these 
drugs and their interactions; and educating patients with regards to drugs 
with the intention of limiting these untoward effects and improving 
compliance. 
Health care 
practice 
Process 
and  
outcomes 
 
Not 
specified 
Not 
specified 
Franklin BD, van 
Mil JW [2005]6 
US/NL Clinical Pharmacy is that part of the practice of pharmacy that contributes 
directly to patient care and develops and promotes the rational and 
appropriate use of medicinal products and devices. 
Health care 
practice 
Process Pharmacist Not 
specified 
American College 
of Clinical 
Pharmacy [2008]7 
US Clinical Pharmacy is a health science discipline in which pharmacists provide 
patient care that optimizes medication therapy and promotes health, 
wellness, and disease prevention. The practice of Clinical Pharmacy 
embraces the philosophy of Pharmaceutical Care; it blends a caring 
orientation with specialized therapeutic knowledge, experience, and 
judgment for the purpose of ensuring optimal patient outcomes. 
‘Discipline’; 
Health care 
practice 
Outcomes Pharmacist Not 
specified 
European Society 
of Clinical 
Pharmacy 15 
Europe A health specialty, which describes the activities and services of the clinical 
pharmacist to develop and promote the rational and appropriate use of 
medicinal products and devices. 
Health care 
practice 
Process Clinical  
pharmacist 
Not 
specified 
ABDA/Deutsche 
Pharmazeutische 
Gesellschaft 
[1998]23  
Germany Clinical Pharmacy is that discipline of Pharmacy, which encompasses the 
optimisation of medication use for and by patients based on pharmaceutical 
natural science  
‘Discipline’ Process Not 
specified 
Not 
specified 
United Kingdom 
Clinical Pharmacy 
Association 
(UKCPA)5 
 
UK The term Clinical Pharmacy […] (is) used generally to describe the 
knowledge, skills and attitudes required by a pharmacist to contribute to 
patient care. As the delivery of healthcare becomes more dependent upon 
successful multidisciplinary co-operation, increasingly pharmacists see their 
contributions in terms of overall patient outcomes. 
Body of 
‘knowledge, 
skills, 
attitudes’ 
 
Outcomes Pharmacist Not 
specified 
Belgian Federal 
Government 
Working Group on 
Clinical Pharmacy 
Belgium Clinical pharmacy envisions responsible patient-centered pharmaceutical 
care and the provision of efficient, effective and safe pharmacotherapy 
seamlessly assured by a multidisciplinary care team within a global health 
policy. 
Health care 
practice 
Process Not 
specified 
Not 
specified 
Swiss association of 
Public Health 
Administration and 
Hospital 
Pharmacists (GASA) 
[2011]24 
 
Switzerland Clinical pharmacy is that part of pharmacy that aims to develop and advance 
the appropriate and efficient use of medicines. In hospitals, the term Clinical 
Pharmacy is used to describe the patient centred pharmaceutical activities 
performed in collaboration with other health care professionals. The Clinical 
Pharmacist has completed specific training and is responsible for his actions. 
‘Part of 
pharmacy’; 
health care 
practice 
Process Pharmacist   Not 
specified 
Italian society of 
Clinical Pharmacy25 
 
Italy The scope of Clinical Pharmacy comprises guaranteeing the safe and 
effective use of medicines by employing  clinical pharmacology, counselling, 
pharmacovigilance, and pharmaceutical technology 
Health care 
practice 
Process Not 
specified 
Not 
specified 
French society of 
Clinical Pharmacy26 
France Clinical Pharmacy is the optimal use of pharmacist's pharmaceutical and 
biomedical judgement and knowledge in order to improve the effectiveness, 
safety, efficiency and accuracy in the use of medicines and medical devices 
when treating patients; and this will be achieved using all educational and 
informative resources, particularly by the use of national and international 
scientific publications and events. 
Health care 
practice 
Process 
and 
outcomes 
Pharmacist Not 
specified 
Norwegian society 
of clinical 
pharmacy [2007]27 
Norway Clinical pharmacy is the use of pharmaceutical expertise, clinical data and 
other relevant information to support correct use of drugs in the individual 
patient. The work is performed by a Master in pharmacy in cooperation with 
physicians, and possibly other health professionals and patients themselves. 
Health care 
practice 
Process Master in 
pharmacy 
(as part of 
a team)   
Not 
specified 
Danish society of 
clinical pharmacy28 
Denmark Clinical pharmacy is a profession, which ensures optimal and rational use of 
medication for the benefit of the patient and society in collaboration 
Health care 
practice 
Process 
and 
Pharmacist 
(as part of 
Not 
specified 
  
 
 
  
between pharmacists, pharmaconomists, other medication professionals 
and the patient 
outcomes a team)   
Table 2: Participant characteristics (n=263) 
Characteristics n % 
Country of origin     
Europe West A  116 44.1 
Europe NorthB  43 16.3 
Europe SouthC  42 16.0 
Europe EastD  36 13.7 
Other E 26 9.9 
Professional background     
Pharmacy student 7 2.7 
Pharmacist 256 97.3 
Completed PhD (or equivalent doctorate obtained by research) 101 38.4 
Completed Diploma or Master’s degree in Clinical Pharmacy awarded by a University 59 22.4 
Completed post-graduate specialist training in Clinical pharmacy* 52 19.8 
Doctoral student 36 13.7 
Other F  24 9.1 
Year of pharmacy degree (where applicable)     
1960 to 1969 5 1.9 
1970 to 1979 35 13.3 
1980 to 1989 48 18.3 
1990 to 1999 63 24.0 
2000 to 2005 41 15.6 
2006 to 2010 44 16.7 
After 2010 20 7.6 
Places of work     
Hospital pharmacy 128 48.7 
University 73 27.8 
Community pharmacy 30 11.4 
Governmental organisation 16 6.1 
Professional organisation 16 6.1 
Two or more 42 16.0 
Professional activities     
Providing Pharmaceutical Care/Clinical Pharmacy services 149 56.7 
Conducting research into Pharmaceutical Care/Clinical Pharmacy 134 51.0 
Teaching Pharmaceutical Care/Clinical Pharmacy 135 51.3 
Managing Pharmaceutical Care/Clinical Pharmacy services 81 30.8 
Other 22 8.4 
Membership in professional organisations     
European Society of Clinical Pharmacy for 1 year or longer 158 60.1 
European Society of Clinical Pharmacy for less than 1 year 75 28.5 
Pharmaceutical Care Network Europe (working for an organisation that is a member) 25 9.5 
Pharmaceutical Care Network Europe (as an individual member) 23 8.7 
Euro Pharm Forum 17 6.5 
OtherG 66 25.1 
A = Austria: 7, Belgium: 14, France: 20, Germany: 13, Ireland: 3, Luxembourg: 1, Netherlands: 19, Northern Ireland: 1, 
Switzerland: 24, United Kingdom: 14; B = Denmark: 18, Finland: 5, Iceland: 2, Norway: 10, Sweden: 8; C = (Greece: 4, Italy: 5, 
Malta: 2, Portugal: 11, Spain: 14, Turkey: 6); D = Croatia: 3, Czech Republic: 6, Estonia: 2, Hungary: 1, Letvia: 1, Macedonia: 1, 
Moldova: 1, Montenegro: 3, Romania: 4, Serbia: 1, Slovakia: 4, Slovenia: 4, Ukraine: 5); E = Asia Middle East [Iraq: 2, Israel: 1, 
Jordan: 1, Palestine: 1, Qatar: 1, Saudi Arabia: 3, UAE: 1]; Asia Far East [China: 1, Indonesia: 2, Japan: 2, Phillipines: 1]; Africa 
[Algeria: 1, Libya: 1, Morocco: 1, Nigeria: 1, Tunesia: 1]; North America [Canada: 1, USA: 2]; South America  [Costa Rica: 1, Sint 
Maarten: 1]; F = Clinical pharmacy resident: 2, Independent Prescriber: 1, MPH or MSc in related discipline (MPH, 
pharmacology): 4, Pharm.D. (US): 3, Specialisation in hospital pharmacy: 6, Specialisation in pharmaco-economics: 1,University 
lecturer or professor: 7); G=National society for clinical pharmacy: 22, other academic organisation: 8, other professional 
organisation: 36 
 
  
Table 3: Questionnaire items with <80% agreement on whether they applied to Clinical Pharmacy and participant characteristics associated with stating the item applied to 
Clinical Pharmacy. Where two sets of odds ratios are provided for the same item, the upper row includes the univariate and the second row the adjusted odds ratios, 
respectively. 
Questionnaire item  
(number, proportion of participants stating the 
item applied to Clinical Pharmacy) 
Participant characteristics  
OR and adjusted OR (95% confidence interval) of linking each item to Clinical Pharmacy 
Geographical origin 
(Europe West is reference) 
Pharmacy 
degree 
after 2000 vs 
2000 or earlier 
Active in 
teaching or 
research vs no 
such activity  
Work  in 
hospital vs 
other  Europe 
North 
Europe 
 East 
Europe  
South 
None- 
European 
Professional activities        
Public health promotion  
(n=175; 66.5%) 
0.85 
(0.42, 1.73) 
1.39 
(0.62, 3.10) 
1.53 
(0.71, 3.29) 
4.69 
(1.33, 16.5) 
0.96 
(0.58, 1.62) 
1.08 
(0.62, 1.87) 
1.13 
(0.68, 1.89) 
Drug administration  
(n=112; 42.6%) 
1.07 
(0.53, 2.16) 
1.17 
(0.55, 2.47) 
1.87 
(0.89, 3.90) 
3.11 
(1.16, 8.31) 
1.19 
(0.72, 1.95) 
0.83 
(0.49, 1.42) 
0.86 
(0.53, 1.40) 
Dispensing  
(n=119; 45.2%) 
0.78 
(0.38, 1.61) 
0.94 
(0.44, 2.01) 
1.76 
(0.86, 3.59) 
1.54 
(0.86, 3.62) 
0.90 
(0.55, 1.47) 
0.47** 
(0.28, 0.81) 
0.95 
(0.58, 1.54) 
 Not  
included 
Not  
included 
Not  
included 
Not  
included 
Not  
included 
0.43** 
(0.24, 0.76) 
0.75  
(0.44, 1.26) 
Drug logistics  
(n=104; 39.5%) 
1.72 
(0.82, 3.58) 
2.93** 
(1.36, 6.34) 
4.27** 
(2.03, 8.98) 
1.64 
(0.67, 3.99) 
0.81 
(0.49, 1.33) 
0.56** 
(0.33, 0.95) 
0.41** 
(0.25, 0.69) 
 1.40  
(0.69, 2.92) 
2.36** 
(1.08, 5.13) 
3.21**  
(1.53, 6.74) 
1.47  
(0.58, 3.73) 
Not  
included 
0.40** 
(0.22, 0.75) 
0.33**  
(0.18, 0.59) 
Compounding  
(n=76; 28.9%) 
0.92 
(0.39, 2.15) 
1.73 
(0.76, 3.93) 
3.15** 
(1.49, 6.64) 
1.83 
(0.73, 4.59) 
1.05 
(0.61, 1.80) 
0.38** 
(0.22, 0.67) 
1.00 
(0.59, 1.71) 
 0.90 
(0.38, 2.13) 
1.47 
(0.64, 3.42) 
2.93** 
(1.37, 6.29) 
1.86 
(0.73, 4.74) 
Not  
included 
0.33** 
(0.20, 0.69) 
Not  
included 
Providers of Clinical Pharmacy and/or Pharmaceutical Care services 
Non-pharmacist HCP  
(n=66; 25.2%) 
1.56 
(0.74, 3.26) 
0.75 
(0.31, 1.82) 
0.36* 
(0.13, 0.98) 
0.63 
(0.22, 1.80) 
0.77 
(0.44, 1.37) 
1.54 
(0.81, 2.91) 
0.78 
(0.44, 1.36) 
 1.56 
(0.74, 3.26) 
0.75 
(0.31, 1.82) 
0.36* 
(0.13, 0.98) 
0.63 
(0.22, 1.80) 
Not  
included  
Not  
included 
Not  
included 
Settings for the provision of Clinical Pharmacy and/or Pharmaceutical Care services 
Physician’s practice  
(n=200; 75.9%) 
3.40 * 
(1.12, 10.3) 
0.79 
(0.35, 1.80) 
1.70 
(0.33, 1.50) 
1.16 
(0.43, 3.17) 
0.83 
(0.47, 1.45) 
1.21 
(0.66, 2.19) 
0.76 
(0.43, 1.33) 
 3.40 * 
(1.12, 10.3) 
0.79 
(0.35, 1.80) 
1.70 
(0.33, 1.50) 
1.16 
(0.43, 3.17) 
Not  
included 
Not  
included 
Not  
included 
Community pharmacy  
(n=186; 70.7%) 
0.63 
(0.29, 1.36) 
0.54 
(0.24, 1.20) 
0.45* 
(0.21, 0.95) 
1.01 
(0.37, 2.77) 
0.85 
(0.49, 1.45) 
1.03 
(0.58, 1.82) 
0.96 
(0.57, 1.64) 
 0.63 
(0.29, 1.36) 
0.54 
(0.24, 1.20) 
0.45* 
(0.21, 0.95) 
1.01 
(0.37, 2.77) 
Not  
included 
Not  
included 
Not  
included 
Patient’s home  
(n=180; 68.3%) 
1.77 
(0.77, 4.07) 
0.74 
(0.34, 1.60) 
0.76 
(0.37, 1.59) 
1.05 
(0.42, 2.64) 
0.74 
(0.44, 1.25) 
1.51 
(0.87, 2.62) 
0.65 
(0.39, 1.10) 
Other private/public space (n=143; 54.4%) 0.53 
(0.25, 1.13) 
1.72 
(0.81, 3.67) 
1.64 
(0.81, 3.35) 
0.90 
(0.38, 2.13) 
0.86 
(0.53, 1.40) 
1.13 
(0.67, 1.91) 
1.06 
(0.65, 1.72) 
Key: *p<0.05;  ** p<0.01 
